Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Breast Implant PMA Timeframes Tested By Inamed “Not-Approvable” Letter

This article was originally published in The Gray Sheet

Executive Summary

Firms seeking premarket approval for silicone breast implants should conduct tests designed to more closely predict rupture and gel bleed under real-world conditions, according to new FDA draft guidelines

Related Content

Inamed To Carry On Quest For Silicone Implant Approval After Panel Rejection
Rejected Device Applicants Conserve R&D Resources, Sidestep Confrontation
Inamed To File Next-Gen Breast Implant PMA, Lap-Band NCD Request Soon
Mentor Files Silicone Implant PMA Amendment, Catches Up To Inamed
Inamed augments PMA filing
Mentor Breast Implant Sales Up 23% Despite Silicone Approval Delay
Lap-Band DTC Ad Campaign Aims To Nourish Already Robust Obesity Sales
High-Viscosity Saline Breast Implants Will Jump-Start The Market – PDC CEO
Breast implant guidance
Inamed Stresses Hylaform Non-Inferiority; EU Clears Silicone Implant Safety



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts